Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Victor R. Gordeuk is active.

Publication


Featured researches published by Victor R. Gordeuk.


The New England Journal of Medicine | 1992

Iron overload in Africa. Interaction between a gene and dietary iron content.

Victor R. Gordeuk; Joshua Mukiibi; Sandra J. Hasstedt; Wade S. Samowitz; Corwin Q. Edwards; George L. West; Solomon Ndambire; Jean Emmanual; Neal Nkanza; Zivanai Chapanduka; Maurice Randall; Paul Boone; Paula J. Romano; R. W. Martell; Toyoko S. Yamashita; Paul Effler; Gary M. Brittenham

BACKGROUND AND METHODS In contrast to hemochromatosis, which in white populations is inherited through a gene linked to the HLA locus, iron overload in sub-Saharan Africa is believed to result solely from increased dietary iron derived from traditional home-brewed beer. To examine the hypothesis that African iron overload also involves a genetic factor, we used likelihood analysis to test for an interaction between a gene (the hypothesized iron-loading locus) and an environmental factor (increased dietary iron) that determines transferrin saturation and unsaturated iron-binding capacity. We studied 236 members of 36 African families chosen because they contained index subjects with iron overload. Linkage to the HLA region was tested with use of lod scores. RESULTS In the index subjects, increased iron was present in both hepatocytes and cells of the mononuclear-phagocyte system. Among family members with increased dietary iron due to the consumption of traditional beer, transferrin saturation in serum was distributed bimodally, with 56 normal values (less than 60 percent saturation) and 44 elevated values; the mean serum ferritin concentration was five times higher in the subjects with elevated transferrin saturation (P less than 0.005). The pedigree analysis provided evidence of both a genetic effect (P less than 0.005) and an effect of increased dietary iron (P less than 0.005) on transferrin saturation and unsaturated iron-binding capacity. In the most likely model, increased dietary iron raised the mean transferrin saturation from 30 to 81 percent and lowered the mean unsaturated iron-binding capacity from 38 to 13 mumol per liter in subjects heterozygous for the iron-loading locus. The hypothesis of tight linkage to HLA was rejected. CONCLUSIONS Iron overload in Africa may be caused by an interaction between the amount of dietary iron and a gene distinct from any HLA-linked gene.


The New England Journal of Medicine | 1992

Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria.

Victor R. Gordeuk; Philip E. Thuma; Gary M. Brittenham; Christine E. McLaren; Dean Parry; Anita Backenstose; Godfrey Biemba; Roland Msiska; Laura Holmes; Elizabeth McKinley; Linda Vargas; Robert Gilkeson; Anton A. Poltera

BACKGROUND Cerebral malaria is a severe complication of Plasmodium falciparum infection in children, with a mortality rate of 15 to 50 percent despite antimalarial therapy. METHODS To determine whether combining iron chelation with quinine therapy speeds the recovery of consciousness, we conducted a randomized, double-blind, placebo-controlled trial of the iron chelator deferoxamine in 83 Zambian children with cerebral malaria. To be enrolled, patients had to be less than six years old, have P. falciparum parasitemia, have normal cerebrospinal fluid without evidence of bacterial infection, and be in a coma from which they could not be aroused. Deferoxamine (100 mg per kilogram of body weight per day, infused intravenously for 72 hours) or placebo was added to standard therapy with quinine and sulfadoxine-pyrimethamine. The time to the recovery of full consciousness, time to parasite clearance, and mortality were examined with Cox proportional-hazards regression analysis. RESULTS The rate of recovery of full consciousness among the 42 patients given deferoxamine was 1.3 times that among the 41 given placebo (95 percent confidence interval, 0.7 to 2.3); the median time to recovery was 20.2 hours in the deferoxamine group and 43.1 hours in the placebo group (P = 0.38). Among 50 patients with deep coma, the rate of recovery of full consciousness was increased 2.2-fold with deferoxamine (95 percent confidence interval, 1.1 to 4.7), decreasing the median recovery time from 68.2 to 24.1 hours (P = 0.03). Among 69 patients for whom data on parasite clearance were available, the rate of clearance with deferoxamine was 2.0 times that with placebo (95 percent confidence interval, 1.2 to 3.6). Among all 83 patients, mortality was 17 percent in the deferoxamine group and 22 percent in the placebo group (P = 0.52). CONCLUSIONS Iron chelation therapy may hasten the clearance of parasitemia and enhance recovery from deep coma in cerebral malaria.


Nature Genetics | 2014

A genetic mechanism for Tibetan high-altitude adaptation

Felipe Lorenzo; Chad D. Huff; Mikko Myllymäki; Benjamin A. Olenchock; Sabina Swierczek; Tsewang Tashi; Victor R. Gordeuk; Tana Wuren; Ri Li Ge; Donald A. McClain; Tahsin M. Khan; Parvaiz A Koul; Prasenjit Guchhait; Mohamed E. Salama; Jinchuan Xing; Gregg L. Semenza; Ella Liberzon; Andrew Wilson; Tatum S. Simonson; Lynn B. Jorde; William G. Kaelin; Peppi Koivunen; Josef T. Prchal

Tibetans do not exhibit increased hemoglobin concentration at high altitude. We describe a high-frequency missense mutation in the EGLN1 gene, which encodes prolyl hydroxylase 2 (PHD2), that contributes to this adaptive response. We show that a variant in EGLN1, c.[12C>G; 380G>C], contributes functionally to the Tibetan high-altitude phenotype. PHD2 triggers the degradation of hypoxia-inducible factors (HIFs), which mediate many physiological responses to hypoxia, including erythropoiesis. The PHD2 p.[Asp4Glu; Cys127Ser] variant exhibits a lower Km value for oxygen, suggesting that it promotes increased HIF degradation under hypoxic conditions. Whereas hypoxia stimulates the proliferation of wild-type erythroid progenitors, the proliferation of progenitors with the c.[12C>G; 380G>C] mutation in EGLN1 is significantly impaired under hypoxic culture conditions. We show that the c.[12C>G; 380G>C] mutation originated ∼8,000 years ago on the same haplotype previously associated with adaptation to high altitude. The c.[12C>G; 380G>C] mutation abrogates hypoxia-induced and HIF-mediated augmentation of erythropoiesis, which provides a molecular mechanism for the observed protection of Tibetans from polycythemia at high altitude.


Journals of Gerontology Series A-biological Sciences and Medical Sciences | 2014

Testosterone Induces Erythrocytosis via Increased Erythropoietin and Suppressed Hepcidin: Evidence for a New Erythropoietin/Hemoglobin Set Point

Eric Bachman; Thomas G. Travison; Shehzad Basaria; Maithili N. Davda; Wen Guo; Michelle Li; John Connor Westfall; Harold Bae; Victor R. Gordeuk; Shalender Bhasin

BACKGROUND The mechanisms by which testosterone increases hemoglobin and hematocrit remain unclear. METHODS We assessed the hormonal and hematologic responses to testosterone administration in a clinical trial in which older men with mobility limitation were randomized to either placebo or testosterone gel daily for 6 months. RESULTS The 7%-10% increase in hemoglobin and hematocrit, respectively, with testosterone administration was associated with significantly increased erythropoietin (EPO) levels and decreased ferritin and hepcidin levels at 1 and 3 months. At 6 months, EPO and hepcidin levels returned toward baseline in spite of continued testosterone administration, but EPO levels remained nonsuppressed even though elevated hemoglobin and hematocrit higher than at baseline, suggesting a new set point. Consistent with increased iron utilization, soluble transferrin receptor (sTR) levels and ratio of sTR/log ferritin increased significantly in testosterone-treated men. Hormonal and hematologic responses were similar in anemic participants. The majority of testosterone-treated anemic participants increased their hemoglobin into normal range. CONCLUSIONS Testosterone-induced increase in hemoglobin and hematocrit is associated with stimulation of EPO and reduced ferritin and hepcidin concentrations. We propose that testosterone stimulates erythropoiesis by stimulating EPO and recalibrating the set point of EPO in relation to hemoglobin and by increasing iron utilization for erythropoiesis.


Haematologica | 2013

The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe

Mehdi Nouraie; Janet S. Lee; Yingze Zhang; Tamir Kanias; Xuejun Zhao; Zeyu Xiong; Timothy B. Oriss; Qilu Zeng; Gregory J. Kato; J. Simon R. Gibbs; Mariana Hildesheim; Vandana Sachdev; Robyn J. Barst; Roberto F. Machado; Kathryn L. Hassell; Jane A. Little; Dean E. Schraufnagel; Lakshmanan Krishnamurti; Enrico M. Novelli; Reda E. Girgis; Claudia R. Morris; Erika B. Rosenzweig; David B. Badesch; Sophie Lanzkron; Oswaldo Castro; Jonathan C. Goldsmith; Victor R. Gordeuk; Mark T. Gladwin

The intensity of hemolytic anemia has been proposed as an independent risk factor for the development of certain clinical complications of sickle cell disease, such as pulmonary hypertension, hypoxemia and cutaneous leg ulceration. A composite variable derived from several individual markers of hemolysis could facilitate studies of the underlying mechanisms of hemolysis. In this study, we assessed the association of hemolysis with outcomes in sickle cell anemia. A hemolytic component was calculated by principal component analysis from reticulocyte count, serum lactate dehydrogenase, aspartate aminotransferase and total bilirubin concentrations in 415 hemoglobin SS patients. Association of this component with direct markers of hemolysis and clinical outcomes was assessed. As primary validation, both plasma red blood cell microparticles and cell-free hemoglobin concentration were higher in the highest hemolytic component quartile compared to the lowest quartile (P≤0.0001 for both analyses). The hemolytic component was lower with hydroxyurea therapy, higher hemoglobin F, and alpha-thalassemia (P≤0.0005); it was higher with higher systemic pulse pressure, lower oxygen saturation, and greater values for tricuspid regurgitation velocity, left ventricular diastolic dimension and left ventricular mass (all P<0.0001). Two-year follow-up analysis showed that a high hemolytic component was associated with an increased risk of death (hazard ratio, HR 3.44; 95% confidence interval, CI: 1.2–9.5; P=0.02). The hemolytic component reflects direct markers of intravascular hemolysis in patients with sickle cell disease and allows for adjusted analysis of associations between hemolytic severity and clinical outcomes. These results confirm associations between hemolytic rate and pulse pressure, oxygen saturation, increases in Doppler-estimated pulmonary systolic pressures and mortality (Clinicaltrials.gov identifier: NCT00492531).


The New England Journal of Medicine | 2017

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

Kenneth I. Ataga; Abdullah Kutlar; Julie Kanter; Darla Liles; Rodolfo Delfini Cançado; Joao Ricardo Friedrisch; Troy H. Guthrie; Jennifer Knight-Madden; Ofelia Alvarez; Victor R. Gordeuk; Sandra F.M. Gualandro; Marina Pereira Colella; Wally R. Smith; Scott Rollins; Jonathan W. Stocker; Russell P. Rother

Background The up‐regulation of P‐selectin in endothelial cells and platelets contributes to the cell–cell interactions that are involved in the pathogenesis of vaso‐occlusion and sickle cell–related pain crises. The safety and efficacy of crizanlizumab, an antibody against the adhesion molecule P‐selectin, were evaluated in patients with sickle cell disease. Methods In this double‐blind, randomized, placebo‐controlled, phase 2 trial, we assigned patients to receive low‐dose crizanlizumab (2.5 mg per kilogram of body weight), high‐dose crizanlizumab (5.0 mg per kilogram), or placebo, administered intravenously 14 times over a period of 52 weeks. Patients who were receiving concomitant hydroxyurea as well as those not receiving hydroxyurea were included in the study. The primary end point was the annual rate of sickle cell–related pain crises with high‐dose crizanlizumab versus placebo. The annual rate of days hospitalized, the times to first and second crises, annual rates of uncomplicated crises (defined as crises other than the acute chest syndrome, hepatic sequestration, splenic sequestration, or priapism) and the acute chest syndrome, and patient‐reported outcomes were also assessed. Results A total of 198 patients underwent randomization at 60 sites. The median rate of crises per year was 1.63 with high‐dose crizanlizumab versus 2.98 with placebo (indicating a 45.3% lower rate with high‐dose crizanlizumab, P=0.01). The median time to the first crisis was significantly longer with high‐dose crizanlizumab than with placebo (4.07 vs. 1.38 months, P=0.001), as was the median time to the second crisis (10.32 vs. 5.09 months, P=0.02). The median rate of uncomplicated crises per year was 1.08 with high‐dose crizanlizumab, as compared with 2.91 with placebo (indicating a 62.9% lower rate with high‐dose crizanlizumab, P=0.02). Adverse events that occurred in 10% or more of the patients in either active‐treatment group and at a frequency that was at least twice as high as that in the placebo group were arthralgia, diarrhea, pruritus, vomiting, and chest pain. Conclusions In patients with sickle cell disease, crizanlizumab therapy resulted in a significantly lower rate of sickle cell–related pain crises than placebo and was associated with a low incidence of adverse events. (Funded by Selexys Pharmaceuticals and others; SUSTAIN ClinicalTrials.gov number, NCT01895361.)


British Journal of Haematology | 2014

Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia.

Santosh L. Saraf; Xu Zhang; Tamir Kanias; James P. Lash; Robert E. Molokie; Bharvi Oza; Catherine Lai; Julie H. Rowe; Michel Gowhari; Johara Hassan; Joseph DeSimone; Roberto F. Machado; Mark T. Gladwin; Jane A. Little; Victor R. Gordeuk

To evaluate the association between haemoglobinuria and chronic kidney disease (CKD) in sickle cell anaemia (SCA), we analysed 356 adult haemoglobin SS or Sβo thalassaemia patients from the University of Illinois at Chicago (UIC) and 439 from the multi‐centre Walk‐Treatment of Pulmonary Hypertension and Sickle Cell Disease with Sildenafil Therapy (Walk‐PHaSST) cohort. CKD was classified according to National Kidney Foundation Kidney Disease Outcomes Quality Initiatives guidelines. Haemoglobinuria, defined as positive haem on urine dipstick with absent red blood cells on microscopy, was confirmed by enzyme‐linked immunosorbent assay in a subset of patients. The prevalence of CKD was 58% in the UIC cohort and 54% in the Walk‐PHaSST cohort, and haemoglobinuria was observed in 36% and 20% of the patients, respectively. Pathway analysis in both cohorts indicated an independent association of lactate dehydrogenase with haemoglobinuria and, in turn, independent associations of haemoglobinuria and age with CKD (P < 0·0001). After a median of 32 months of follow‐up in the UIC cohort, haemoglobinuria was associated with progression of CKD [halving of estimated glomerular filtration rate or requirement for dialysis; Hazard ratio (HR) 13·9, 95% confidence interval (CI) 1·7–113·2, P = 0·0012] and increasing albuminuria (HR 3·1, 95% CI: 1·3–7·7; logrank P = 0·0035). In conclusion haemoglobinuria is common in SCA and is associated with CKD, consistent with a role for intravascular haemolysis in the pathogenesis of renal dysfunction in SCA.


Blood | 2012

Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans

Harold Bae; Clinton T. Baldwin; Paola Sebastiani; Marilyn J. Telen; Allison E. Ashley-Koch; Melanie E. Garrett; W. Craig Hooper; Christopher J. Bean; Michael R. DeBaun; Dan E. Arking; Pallav Bhatnagar; James F. Casella; Jeffrey R. Keefer; Emily Barron-Casella; Victor R. Gordeuk; Gregory J. Kato; Caterina P. Minniti; James O. Taylor; Andrew D. Campbell; Lori Luchtman-Jones; Carolyn Hoppe; Mark T. Gladwin; Yingze Zhang; Martin H. Steinberg

To the editor: Fetal hemoglobin (HbF) protects against many but not all of the hematologic and clinical complications of sickle cell anemia.[1][1],[2][2] This protection is dependent on the ability of HbF to hinder deoxyHbS polymerization. HbF level is variable and highly heritable. Previous


Pharmacotherapy | 2013

Feasibility of implementing a comprehensive warfarin pharmacogenetics service.

Edith A. Nutescu; Katarzyna Drozda; Adam P. Bress; William L. Galanter; James M. Stevenson; Thomas D. Stamos; Ankit A. Desai; Julio D. Duarte; Victor R. Gordeuk; David Peace; ShriHari S. Kadkol; Carol Dodge; Santosh L. Saraf; John Garofalo; Jerry A. Krishnan; Joe G. N. Garcia; Larisa H. Cavallari

To determine the procedural feasibility of a pharmacist‐led interdisciplinary service for providing genotype‐guided warfarin dosing for hospitalized patients newly starting warfarin.


Biology of Blood and Marrow Transplantation | 2016

Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease

Santosh L. Saraf; Annie L. Oh; Pritesh Patel; Yash Jalundhwala; Karen Sweiss; Matthew Koshy; Sally Campbell-Lee; Michel Gowhari; Johara Hassan; David Peace; John G. Quigley; Irum Khan; Robert E. Molokie; Lewis L. Hsu; Nadim Mahmud; Dennis J. Levinson; A. Simon Pickard; Joe G. N. Garcia; Victor R. Gordeuk; Damiano Rondelli

Allogeneic hematopoietic stem cell transplantation (HSCT) is rarely performed in adult patients with sickle cell disease (SCD). We utilized the chemotherapy-free, alemtuzumab/total body irradiation 300 cGy regimen with sirolimus as post-transplantation immunosuppression in 13 high-risk SCD adult patients between November 2011 and June 2014. Patients received matched related donor (MRD) granulocyte colony-stimulating factor-mobilized peripheral blood stem cells, including 2 cases that were ABO incompatible. Quality-of-life (QoL) measurements were performed at different time points after HSCT. All 13 patients initially engrafted. A stable mixed donor/recipient chimerism was maintained in 12 patients (92%), whereas 1 patient not compliant with sirolimus experienced secondary graft failure. With a median follow-up of 22 months (range, 12 to 44 months) there was no mortality, no acute or chronic graft-versus-host disease (GVHD), and no grades 3 or 4 extramedullary toxicities. At 1 year after transplantation, patients with stable donor chimerism have normalized hemoglobin concentrations and improved cardiopulmonary and QoL parameters including bodily pain, general health, and vitality. In 4 patients, sirolimus was stopped without rejection or SCD-related complications. These results underscore the successful use of a chemotherapy-free regimen in MRD HSCT for high-risk adult SCD patients and demonstrates a high cure rate, absence of GVHD or mortality, and improvement in QoL including the applicability of this regimen in ABO mismatched cases (NCT number 01499888).

Collaboration


Dive into the Victor R. Gordeuk's collaboration.

Top Co-Authors

Avatar

Santosh L. Saraf

University of Illinois at Chicago

View shared research outputs
Top Co-Authors

Avatar

Robert E. Molokie

University of Illinois at Chicago

View shared research outputs
Top Co-Authors

Avatar

Michel Gowhari

University of Illinois at Chicago

View shared research outputs
Top Co-Authors

Avatar

Roberto F. Machado

University of Illinois at Chicago

View shared research outputs
Top Co-Authors

Avatar

Xu Zhang

University of Illinois at Chicago

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jin Han

University of Illinois at Chicago

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Johara Hassan

University of Illinois at Chicago

View shared research outputs
Researchain Logo
Decentralizing Knowledge